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Abstract
Background: The success of anti-TNF biologics for the treatment of rheumatoid arthritis has highlighted the
importance of understanding the intracellular pathways that regulate TNF production in the quest for an orally-
available small molecule inhibitor. p38 is known to strongly regulate TNF production via MK2. The failure of several
p38 inhibitors in the clinic suggests the importance of other downstream pathways in normal cell function. Recent
work has described a ‘substrate-selective’ p38 inhibitor that is able to preferentially block the activity of p38 against
one substrate (MK2) versus another (ATF2). Using a combined experimental and computational approach, we have
examined this mechanism in greater detail for two p38 substrates, MK2 and ATF2.
Results: We found that in a dual (MK2 and ATF2) substrate assay, MK2-p38 interaction reduced the activity of p38
against ATF2. We further constructed a detailed kinetic mechanistic model of p38 phosphorylation in the presence
of multiple substrates and successfully predicted the performance of classical and so-called ‘substrate-selective’ p38
inhibitors in the dual substrate assay. Importantly, it was found that excess MK2 results in a stoichiometric effect in
which the formation of p38-MK2-inhibitor complex prevents the phosphorylation of ATF2, despite the preference
of the compound for the p38-MK2 complex over the p38-ATF2 complex. MK2 and p38 protein expression levels
were quantified in U937, Thp-1 and PBMCs and found that [MK2] > [p38].
Conclusion: Our integrated mechanistic modeling and experimental validation provides an example of how
systems biology approaches can be applied to drug discovery and provide a basis for decision-making with limited
chemical matter. We find that, given our current understanding, it is unlikely that ‘substrate-selective’ inhibitors of
p38 will work as originally intended when placed in the context of more complex cellular environments, largely
due to a stoichiometric excess of MK2 relative to p38.
Background
The precedence for tumor necrosis factor alpha (TNF)
as a target has been well established by the anti-TNF
biological therapeutics currently on the market [1].
While the biologic therapies available are targeted at
TNF directly, TNF production can be regulated at intra-
cellular several points as well, including transcription,
translation and shedding from its membrane-anchored
precursor on the cell surface, all of which have been
pursued as drug targets by various companies [2]. p38
MAPK was originally identified as the target of a com-
pound that regulated the production of multiple pro-
inflammatory cytokines, including TNF. p38’s regulation
of TNF production is largely thought to be mediated via
MK2, one of its many substrates. Active MK2 serves to
stabilize TNF mRNA, thereby positively contributing to
TNF production [3-5].
Dozens of small molecule p38 inhibitors have been
put into the clinic for the treatment of chronic inflam-
matory diseases such as RA [6-9]. These compounds
represent a diverse chemical space [6,7,9] and in spite of
being highly selective [10], none has yet made it to the
market, with many failing due to adverse events, most
notably liver enzyme elevation and skin rashes [11]. It
has been hypothesized that the adverse events may be
mechanistically linked to p38 [12], possibly due to the
disruption of the normal p38 function within the cell,
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covery teams have sought means to provide a more
selective inhibition of TNF production.
It is very attractive to attempt to selectively block TNF
by targeting intracellular signaling mechanisms regulat-
ing its production. Further, it has been surmised that
intervening proximal to TNF (as opposed to blocking
signaling farther upstream) will help avoid unwanted
effects. To this end, MK2 has been investigated as a
potential target [13]. However, MK2 itself has proven to
be a challenging molecule to selectively target with
small molecules [14]. Consequently, attention has
reverted to p38. Based on the established druggability of
p38 as a target, its diverse role in cellular function and
the specific role for MK2 in TNF production it has been
hypothesized that specific modulation of this interaction
would lead to an improved safety profile over previous
p38 inhibitors. This is the basis for the development of
so-called ‘substrate-selective’ inhibitors as described by
D a v i d s o n ,e ta l .[ 1 5 ] .I nD a v i d s o n ,et al.a‘substrate-
selective’ a p38-alpha inhibitor was described that pre-
vented p38-alpha-dependent MK2 phosphorylation (KI,
app = 330 nM) but did not prevent phosphorylation of
another p38 substrate, ATF-2 (KI, app > 20 uM) [15].
The structural details of how this molecule is able to eli-
cit differential inhibition of MK2 and ATF2 were not
disclosed or not known. ATF2 was used as a representa-
tive nuclear localized transcription factor in this assay,
even though it is known to be phosphorylated by other
kinases, such as JNK [16]. ATF2 is a histone acteyltrans-
ferase that binds DNA in a sequence-specific manner
[17]. It activates a variety of gene targets including
cyclin A, cyclin D, and c-jun, which are involved in
oncogenesis [18]. p38 phosphorylates ATF2 on Thr 69
and Thr 71 [19].
Compounds satisfying the ‘substrate-selective’ criteria
can be discovered through high-throughput screening
approaches. Two screens are set up: one looking for
p38-alpha mediated MK-2 phosphorylation and one for
p38alpha mediated ATF2 phosphorylation. Compounds
are selected such that their potency in the MK2 assay >>
ATF2 assay. Thus, by the construction of the screening
campaign, such compounds are said to be ‘substrate-
selective’.
In this work, we investigate the degree to which
‘substrate-selectivity’ holds as these classes of com-
pounds are tested under conditions with multiple
competing substrates. Using a combination of bio-
chemical experiments and kinetic modeling we
explore the contributions of mechanism and stoichio-
metry in determining the feasibility of the ‘substrate-
selective’ mechanism under more complex, multi-sub-
strate conditions.
Results
Previous work has defined a ‘substrate-selective’ p38
inhibitor as a compound that has a lower IC50 for one
of its substrates than another, as assessed in indepen-
dent assays [15]. This behavior has been demonstrated
for a p38 inhibitor described in Davidson, et al
(CMPD1) that exhibited a lower IC50 for MK2 than for
ATF-2, both well-known substrates of p38 [15]. In order
to verify this behavior two assays were developed on the
Meso-Scale Discovery platform, one for the phosphory-
lated form of the transcription factor, ATF2 and one for
phosphorylated form of the kinase MK2, as described in
Methods. In each case, the degree of phosphorylation
serves as a readout of the activity of p38 for its respec-
tive substrate.
We chose to evaluate the compound from the original
Davidson paper, CMPD1 [15] with 2 traditional p38
inhibitors: SD-0006 [7] and BIRB 796 [20].
Using these assays, IC50’so ft h e3c o m p o u n d sw e r e
measured against either MK2 or ATF2, shown in Figure
1. Traditional p38 inhibitors, SD-0006 and BIRB 796,
inhibited MK2 phosphorylation and ATF2 phosphoryla-
tion in a dose-dependent manner with IC50s within 10-
fold of each other (Figure 1, Table 1). By contrast, the
phospho-ATF2 dose-response curve for the CMPD1 are
significantly right-shifted relative to the phospho-MK2
dose-response curve. Similar results were obtained for
an in-house substrate-selective compound (data not
shown).
ATF2/MK2 Dual Substrate Assay
We next sought to determine how substrate-selective
compounds would behave in a context where multiple
competing substrates were present. To this end, we
d e s i g n e dad u a l - s u b s t r a t ea s s a yi nw h i c hp 3 8c o u l d
simultaneously phosphorylate MK2 and/or ATF2. The
assay conditions chosen were 0.5 nM p38, 100 nM
A T F 2 ,1 0n MM K 2 ,5 0u MA T P .A sw i t ht h es i n g l e
substrate assay, MK2 phosphorylation was assayed at 30
min and ATF2 phosphorylation was assayed at 120 min
to ensure that each measurement was within the linear
range of the assay. ATP levels were measured at the end
of the assay, to confirm that it was not being depleted.
The dual substrate assay was run in the absence of
compound to examine the effect of the second substrate.
In the absence of compound, the addition of ATF2 had
no discernable effect on MK2 phosphorylation (Figure
2a). Conversely, we found that addition of MK2 mark-
edly inhibited ATF2 phosphorylation, as one might
expect given that MK2 has a much higher affinity for
p38 than ATF2 (Figure 2b).
In order to aid in the interpretation of the dual sub-
strate assay, we developed a simple kinetic model of
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and MK2 (diagrammed in Figure 3a). Since p38 has a
single kinase domain and ATP binding site, we assumed
that p38 can only act on a single substrate at a time.
For each substrate, a random-order bi-substrate (sub-
strate + ATP) reaction mechanism was assumed. Active
p38 can reversibly bind ATP, with affinity KD, ATP and
ATP binding is independent of further complex forma-
tion. Active p38 (ATP bound and unbound) can reversi-
bly bind to ATF2 or MK2 to form complexes p38-ATF2
or p38-MK2, respectively. Each complex undergoes an
irreversible catalysis step to form products phospho-
ATF2 (and ADP) or phospho-MK2 (and ADP). The
model equations are a set of ordinary differential equa-
tions written in terms of mass-action kinetics. Binding
interactions are characterized by affinities KD, ATF2 or
KD, MK2, respectively, as listed in Table 2. Catalysis rates
kcat, ATF2 and kcat, MK2 are also listed in Table 2. For the
c a s ew h e r eo n l yo n es u b s t r a t ei sp r e s e n t ,t h i sm o d e l
reduces to the single substrate assay.
Using this simple competitive model, we simulated the
single and dual-substrate assays (Figure 3b). The simula-
tion results over a 120 min time scale indicate very
subtle differences in ATF2 phosphorylation between the
single and dual substrate assays. However, the experi-
mental results from the dual substrate assay indicate a
far more pronounced inhibition of ATF2 phosphoryla-
tion in the dual substrate assay than seen in the simula-
tion results. Thus, this basic competitive mechanism
was not quantitatively consistent with the experimental
data and prompted us to examine the basic mechanism
further.
We next experimentally measured the effect of MK2
levels on the degree of ATF2 phosphorylation for a
fixed concentration of p38. This demonstrated that the
inhibition of ATF2 phosphorylation by MK2 was dose-
dependent. (Figure 4a). Secondly, we questioned
whether the inhibition effect was due to MK2 specifi-
cally, or simply required any second p38 substrate. For
this we chose to use another known p38 substrate, ‘pep-
tide 4’ [21]. In our assays, the true Km of this peptide
was determined to be roughly 40 uM (data not shown).
The inhibition of ATF2 phosphorylation was measured
in the presence of peptide 4 at 0, 25, 50 and 100 uM,
and shown to have no effect on phospho-ATF2, inde-
pendent of p38 levels used (Figure 4b).
In order to explain the MK2-induced inhibition of
ATF2 phosphorylation seen in the experimental data,
we hypothesized five alternate mechanisms: [1] phos-
pho-MK2 was inhibiting p38 via substrate inhibition; [2]
phospho-MK2 was binding ATF2 preventing its interac-
tion with p38; or [3-5] p38 itself is modified after phos-
phorylating MK2 either by [3] altering its affinity for
ATP, [4] altering its affinity for ATF2 or [5] altering its
Figure 1 Single substrate assay. Phospho-MK2 (Δ) or phospho-
ATF2 (▽) was measured at 30 min or 120 min, respectively in the
single substrate assay. Data are shown as a fraction of the
maximum signal for varying amounts of compound treatment: A,
SD-0006, B, BIRB 796, C, CMPD1. IC50 values for each compound/
substrate are listed in Table 1. Data is shown ± standard deviation
(n = 2)
Table 1 Single Substrate Assay: Compound IC50 Values
(uM)
Compound phospho-MK2 phospho-ATF2 substrate selectivity*
SD-0006 0.11 ± 1.2 0.35 ± 1.1 3.3
BIRB 796 7.75 ± 1.3 0.92 ± 1.1 0.12
CMPD1 23.4 ± 1.9 >400** >17
IC50’s are shown ± standard error.
*Substrate Selectivity is defined as a relative measure between inhibiting
phospho-ATF2 and phospho-MK2 = (ATF2 IC50)/(MK2 IC50). This quantity is
distinct and separable from a compound’s potency.
**CMPD1 is unable to completely inhibit phospho-ATF2 within its solubility
limits.
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into the corresponding biochemical reaction scheme
(diagrammed in Figure 5). For each reaction scheme the
single and dual substrate assays were simulated (Figure
6, columns 1 & 2), as well as the dose-dependence on
MK2 levels (Figure 6, column 3).
Mechanism #1
In this mechanism, substrates are permitted to rebind to
p38 after getting phosphorylated. While this mechanism
successfully impedes ATF2 phosphorylation, it can
nonetheless be ruled out because it is predicted to
reduce overall MK2 phosphorylation. Further, this sub-
strate inhibition mechanism fails to reproduce the
observed dose-dependence on MK2 concentration (Fig-
ure 6). If phospho-MK2 stays associated with p38 it will
affect p38’s ability to further phosphorylate other MK2
molecules resulting in the decrease in overall p-MK2.
Finally, this mechanism also did not show sufficient sen-
sitivity to MK2 levels as seen in the MK2 dose-response
curve. Intuitively this occurs because MK2 levels already
exceed p38 level in the assay, consequently, p38 is
quickly saturated by phospho-MK2.
Mechanism #2
In this mechanism, MK2 is allowed to bind ATF2 and
prevent its interaction with p38. Intuitively, this
mechanism is limited by the stoichiometry of the assay,
Figure 2 Dual substrate assay. A, the time course of MK2 phosphorylation by p38 is measured in the presence (□) or absence (Δ)o f1 0 0n M
ATF2. No MK2 (ATF2 only, ▽) and no enzyme (×) are shown as controls. B, the time course of ATF2 phosphorylation by p38 is measured in the
presence (□) or absence (▽) of 10 nM MK2. No ATF2 (MK2 only, Δ) and no enzyme (×) are shown as controls. Data is shown ± standard
deviation (n = 4).
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ATF2. Consequently, this mechanism can be ruled out
because no effect was seen on MK2 in addition to an
insufficient magnitude of effect on the MK2 dose-
response curve at high MK2 concentrations.
Mechanisms #3-5
The remaining mechanisms investigate 3 ways in which
the activity of the p38 kinase might be altered following
interaction with MK2. In mechanism #3, MK2 alters the
affinity of p38 for ATP. In this case, phosphorylation of
ATF2 is significantly inhibited. By contrast, phospho-
MK2 is relatively unaffected due to its high affinity for
p38. However, this mechanism shows little to no sensi-
tivity to MK2 concentration and can consequently be
ruled out as an independent mechanism.
Mechanisms #4 and #5 posit that MK2 alters the affi-
nity for ATF2 (KD, ATF2) and the catalytic activity (kcat)
of p38, respectively. Each parameter was assumed to be
affected 10-fold. In both cases, these mechanisms are
qualitatively consistent with the observed data. They
have no discernable effect on phosphorylation of MK2,
while dramatically inhibiting phosphorylation of ATF2.
Further, each shows a dose-dependence with total MK2
concentration.
Model validation
In order to validate the model, we aimed to predict and
measure the behavior of a perfectly non-substrate selective
p38 inhibitor. Since we cannot be guaranteed that any of
the compounds exhibit this idealized behavior we devised
a ‘virtual p38 compound’ that could be tested experimen-
tally. Conceptually, an ideal non-substrate-selective inhibi-
tor of p38 would bind p38 and prevent its activity,
effectively titrating out the p38. Experimentally and
Figure 3 Base kinetic model. A, the base kinetic mechanism for p38 competition with two substrates in a random order bi-substrate reaction.
After reversibly binding ATP and a second substrate (ATF2 or MK2) in random order, the ternary complex undergoes an irreversible
phosphorylation step to create phosphorylated product, ADP and recover the active p38. Kinetic parameters are listed in Table 2. B, kinetic
simulation of the base kinetic mechanism 0.5 nM p38, 50 uM ATP, 10 nM MK2 and 100 nM ATF2. Results are virtually indistinguishable from MK2
only condition for phospho-MK2 and from ATF2 only condition for phospho-ATF2.
Table 2 Biochemical Kinetic Model Parameters
Name Description Value Units Reference
KD, ATP ATP-p38 affinity 67 uM In-house
measurement
KD, ATF2 ATF2-p38 affinity 38 uM [30]
KD, MK2 MK2-p38 affinity 20 nM [31]
kcat,
ATF2













[p38] p38 (active) initial
condition
0.5 nM
[ATP] ATP initial condition 50 uM
[ATF2] ATF2 initial condition 100 nM
[MK2] MK2 initial condition 10 nM
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ing the p38 level in concordance with a simple inhibitor-
p38 binding isotherm (fraction of p38 bound by inhibitor =
[Inhibitor]/([Inhibitor] + KI). The resulting relationship
between ‘virtual compound’ and free p38 is shown in
Figure 7a. Using the model, the virtual inhibitor is simu-
lated. Mechanisms #4 & #5 predict a discernable left-
shift in IC50 for the dual-substrate assay and no effect on
the phospho-MK2 assay (Figure 7b). The magnitude of
the shift in each case is dependent on how much the cor-
responding parameter is affected following MK2 interac-
tion. The ‘virtual compound’ was tested in the single and
dual substrate assays, shown in Figure 7c. As predicted
with the kinetic model, there was no effect on the MK2
IC50 and a significant left-shift in the ATF2 IC50.T h u s ,
the simple presence of MK2 reduces the ability of p38 to
phosphorylate ATF2, even in the absence of compound.
Further, this effect is qualitatively and quantitatively con-
sistent with MK2 altering p38’s affinity and/or catalytic
activity for ATF2.
If the p38-MK2 interaction affected p38’ss u b s e q u e n t
ability to phosphorylate ATF2, we predict that p38
should have a markedly different ability to phosphorylate
ATF2 with and without pre-incubation with MK2. To
test this, p38 was incubated with different amounts of
MK2 for 120 min, under the same reaction conditions as
in the single substrate assay. Following incubation, p38
w a si m m u n o p r e c i p i t a t e dt or e m o v ei tf r o mM K 2 .T h e
immunoprecipitates were analyzed by Western blot to
demonstrate there was no MK2 contamination (data not
shown). Finally, the immunoprecipitated p38 was then
used in a subsequent reaction with ATF2 and phospho-
ATF2 measured after 120 min of incubation time. As
shown in Figure 8, pre-incubation with MK2 dramatically
inhibited the ability of p38 to phosphorylate ATF2.
Having validated the model and developed a grasp of
the potential mechanisms underlying the behavior of the
dual substrate assay, we then sought to simulate the
effects of both classical and substrate-selective p38 inhi-
bitors. A classical, non-substrate-selective p38 inhibitor
Figure 4 MK2 dependence. A, phosphorylation of ATF2 by p38 was measured for varying concentrations of MK2 in dual substrate assay (n =
2). B, phosphorylation of ATF2 by p38 was measured for in the presence of peptide 4 and for varying p38 levels (n = 4). Data is presented as
the fraction of the maximum signal. Data is shown ± standard deviation.
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model an inhibitor that could interact with all forms of
p38 with equal affinity, characterized by KI.I no r d e rt o
simulate the presence of a ‘substrate-selective’ com-
pound we added a compound to the kinetic model that
binds the p38-MK2 complex with affinity KI.T h ec o m -
pound was allowed to bind to free p38 and p38-ATF2
with a reduced affinity KD,I /(1-f)w h e r ef is the selectiv-
ity (1 = perfect selectivity; 0 = no selectivity). This com-
pound serves to stabilize the p38-MK2 complex and
thus the MK2 dissociation rate constant must be multi-
plied by (1-f) to satisfy thermodynamic constraints of
microscopic reversibility. For our purposes, we assumed
a highly potent and selective compound with KI =1n M
and f = 0.99. The details of kinetic mechanisms are car-
tooned in Figure 9. Both ATP-competitive and ATP
non-competitive compounds were simulated.
Dose-response curves were simulated for classical and
substrate-selective inhibitors, predicting the effects on
phospho-ATF2 and phospho-MK2 for both the single
and dual substrate assays (Figure 10). Inhibitor dose-
response curves for the phospho-ATF2 and phospho-
MK2 measurements were generated at the 120 and 30
min time points, respectively. The model simulations
p r e d i c tt h a ta so n em o v e sf r o mt h es i n g l es u b s t r a t e
assay to the dual substrate assay, there will be a left-
shift in phospho-ATF2 IC50 for the classical p38 inhibi-
tors and an even greater left-shift for the substrate-
selective inhibitors. Meanwhile, the simulations pre-
dicted no change in the phospho-MK2 IC50 between the
single and dual substrate assay for either inhibitor.
Simulation results are shown in Figure 10. Both ATP-
competitive and ATP non-competitive compounds had
qualitatively indistinguishable results.
Compound Evaluation
We next tested our set of compounds in the dual sub-
strate assay. All compounds were run in the single and
dual substrate assays and IC50’s determined for phos-
pho-ATF2 and phospho-MK2 (Figure 11 & Table 3). As
Figure 5 Alternate kinetic mechanisms. A, substrate inhibition (mechanism #1 in main text): MK2 and ATF2 are allowed to rebind p38 after
phosphorylation. B, phospho-MK2 binds ATF2 (mechanism #2 in main text): phosphorylated MK2 is allowed to bind unphosphorylated ATF2 and
prevent its interaction with p38. C, altered p38 (mechanisms #3-5 in main text): after phosphorylating MK2, p38 is left in an altered state such
that it has either an altered affinity for ATP (mechanism #3 in main text; indicated by #), an altered affinity for ATF2 (mechanism #4 in main text;
indicated by ##) or an altered catalytic rate for ATF2 (mechanism #5 in main text; indicated by ###).
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on MK2 IC50. Further, the model correctly predicted a
left-shift in ATF2 IC50, regardless of whether or not the
compound was ‘substrate-selective’.T h e r ew e r et w o
novel findings that were correctly predicted via the
modeling effort: (i) the substrate-selective inhibitor
showed a loss of substrate-selective behavior in the dual
substrate assays and (ii) the classical p38 inhibitors also
showed a decrease in the ATF2 IC50 in the dual sub-
strate assay. The loss of substrate-selectivity in the dual
substrate assay was also replicated with a proprietary
substrate-selective compound (data not shown).
The modest left-shift predicted and experimentally
observed in phospho-ATF2 IC50 in the classical inhibi-
tors is due to the effect of MK2 on p38’s ability to phos-
phorylate ATF2. The greater left-shift seen in substrate-
selective inhibitors can be broken down into two parts:
(i) the MK2-mediated effect on p38 and a second effect
(ii): Mechanistically, a substrate-selective compound is
designed to stabilize the p38-MK2 complex (in an inac-
tive state). When compound is added, mass-action
drives the formation of the p38-MK2-compound com-
plex. Since [MK2] > [p38] in our assay design, all of the
active p38 will be sequestered into the p38-MK2-inhibi-
tor complex, reducing the pool of active p38 that is free
to phosphorylate ATF2, in spite of the apparent ‘sub-
strate-selective’ behavior seen in the single assays.
Cell Characterization
Thus far, we have demonstrated both in silico and bio-
chemically, that the presence of additional substrates
results in the loss of substrate selectivity. Due to the
sequestration effect of substrate selective compounds,
we have found that a necessary condition for this to
take place in vivo is that [active p38] < [MK2]. In order
to see if this holds in relevant cell types, we measured
protein expression levels of p38 and MK2 in the PMA-
activated U937 and Thp-1 monocytic cell lines as well
as in primary peripheral blood mononuclear cells
(PBMCs). Protein expression was measured via Western
blot on a per cell basis using recombinant standards and
quantifying bands via densitometry, shown in Figure 12.
Figure 6 Alternate mechanism simulations. A, time courses of phospho-MK2 (1
st column) or phospho-ATF2 (2
nd column) were simulated for
the kinetic mechanisms detailed in Figure 5. Time courses were simulated for the single substrate (10 nM or 100 nM ATF2, dashed line) or the
dual substrate assay (solid line, 10 nM and 100 nM ATF2). B, the dose-dependence phospho-ATF2 was simulated as a function of MK2 for each
kinetic mechanism.
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Page 8 of 17Figure 7 Virtual compound experiment. A, the relationship between free p38 and a ‘virtual p38 inhibitor’ is shown schematically. B, the dose-
response of ATF2 phosphorylation is simulated for the virtual p38 inhibitor using multiple kinetic mechanisms. C, phosphorylation of MK2 (top)
and ATF2 (bottom) by p38 was experimentally measured for varying concentrations of the ‘virtual p38 inhibitor’ under presence of 10 nM MK2
and 100 nM ATF2. The IC50 of the ‘virtual p38 inhibitor’ for phospho-MK2 and phospho-ATF2 are listed in Table 3. Data is shown ± standard
deviation (n = 4).
Figure 8 Immunoprecipitation experiment. A, Schematic of experimental design for immunoprecipitation experiment. p38 was incubated
with varying amounts of MK2 as described in Methods. Following reaction, total p38 was immunoprecipitated and then reacted with 100 nM
ATF2. B, ATF2 phosphorylation, following the experimental design described in A, was measured for varying MK2 concentrations.
Hendriks et al. BMC Systems Biology 2010, 4:23
http://www.biomedcentral.com/1752-0509/4/23
Page 9 of 17In both U937 and Thp-1 cells, there are comparable
protein levels of p38 and MK2 and in PBMCs the total
protein level of MK2 significantly exceeds the total pro-
tein level of p38. Further, given that not all p38 in a cell
is in the active conformation, our data strongly suggests
that in situ [active p38] < [MK2]. This is also consistent
with other reports of protein expression levels seen in
MAPK signaling cascades [22]. Under these conditions
one would expect the sequestration effect of substrate-
selective compounds to take place.
Discussion
The concept of a ‘substrate-selective’ inhibitor as a means
to avoid unwanted side-effects is a very attractive one. The
use of multiple screening assays to identify such com-
pounds is a convenient and efficient method for identify-
ing chemical entities with specific effects. However, great
care should be taken to understand the cellular target(s) to
determine the feasibility of such strategies particularly in
more complex environments. From this work we specifi-
cally sought to explore the parameters governing the effec-
tiveness of the substrate-selective inhibitor strategy in
general and in particular for the p38-MK2 system.
On the path to understanding the behavior of sub-
strate-selective inhibitors, an additional mechanism was
uncovered: following interaction with MK2, the activity
of p38 with regard to ATF2 is substantially reduced.
From our analysis, there are multiple mechanisms that
could give rise to this, including alteration of the affinity
for ATF2 or the catalytic rate constant. Further determi-
nation of kinetic mechanism and molecular details was
beyond the scope of this work. One might hypothesize
that MK2 may, in some way, be eliciting an inhibitory
phosphorylation on p38, however, this remains to be
demonstrated.
Given that MK2 already has a much higher affinity for
p38 than ATF2, one may ask how ATF2 would get
phosphorylated at all within the cell (knowing that there
is abundant cell-based experimental evidence to this
end). In this case, one must recall that these are com-
peting kinetic processes, rather than static events. Our
dual substrate assay time course (Figure 2B) confirms
that ATF2 phosphorylation continues at a measurable
pace, albeit on a slower time-scale than MK2 (and
including MK2’s inhibition of p38-mediated ATF2 phos-
phorylation). Thus, abundant MK2 does not prevent
Figure 9 Inhibitor kinetic mechanism. The kinetic mechanism for a non-competitive and/or ATP-competitive p38 inhibitor is shown. Substrate-
selective inhibitors are mechanistically described by altering the appropriate rate constants, indicated with * and **.
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merely slows it down. Simulations (Figure 6) further
demonstrate that marked ATF2 phosphorylation is also
quantitatively consistent with reported affinities of p38
for ATF2 and MK2. Even though p38 has markedly dif-
ferent affinities for ATF2 and MK2, we have demon-
strated experimentally and computationally, that both
substrates may get phosphorylated in a biochemical sys-
t e mw i t ht h ek e yd i f f e r e n c eb e i n gt h et i m es c a l eo v e r
which they occur. Further, this work demonstrates that
when ATF2 and MK2 are both present, a so-called ‘p38
substrate-selective’ inhibitor will inhibit the p38-
mediated phosphorylation of both substrates comparably
as a consequence of a sequestration phenomenon driven
by an excess of MK2 relative to active p38.
We have used our computational model to predict
that the introduction of multiple substrates would result
in the loss of substrate selectivity and experimentally
validated this finding in a biochemical assay. Alternately
stated, the addition of MK2 to the p38-ATF2 reaction
was able to make CMPD1 a potent inhibitor of ATF2
phosphorylation. Through the construction of a kinetic
model of the proposed mechanism of action we demon-
strate that these findings are a general result and not a
compound-specific finding. Our analysis demonstrated
that relative p38 and MK2 levels play a defining role in
determining that the substrate-selective mechanism is
not likely to work as intended in vivo. Additionally, this
mechanism of sequestration-mediated inhibition of sec-
ondary substrates would extend to other substrates than
ATF2 as well. It is worth noting that the presence of
scaffolding proteins and higher-order interactions taking
place in the cell that may locally alter protein concentra-
tion and drive interaction that would otherwise not take
place in free solution. One cannot explicitly model such
effects, however, given that their purpose is to locally
Figure 10 Inhibitor simulations. The dose-response of phospho-ATF2 and phospho-MK2 are simulated for A, classical p38 inhibitors and B,
substrate-selective p38 inhibitors. Solid lines indicate results from single substrate assay and dashed lines indicate results for dual substrate assay.
Association rate constants of inhibitors are assumed to be diffusion-limited and inhibitor concentrations are normalized by their affinities (KD).
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Page 11 of 17increase protein concentration it is unlikely to change
the outcome of our analysis.
In our kinetic model, we modeled each phosphoryla-
tion event as a one-hit reaction, even though p38 is
known to phosphorylate MK2 and ATF2 at multiple
sites (Thr 222, Ser 272 and Thr 334 for MK2 and Thr
69 and Thr 71 for ATF2). This was done to restrict the
number of kinetic parameters in the model to as few as
needed to adequately recapture the overall system beha-
vior and be consistent with the experimentally measur-
able quantities, namely single phosphorylation sites.
Conceptually, one could consider p38-mediated phos-
phorylation or activation as the process by which p38
comes into contact with one of its substrates and per-
forms the necessary modifications, either via one single-
step reaction, or multiple dissociation and rebinding
events. In order to perturb this process a compound
needs to interfere with only one of these events. Our
experimental data confirm that our compounds are able
to interfere with MK2 and/or ATF2 phosphorylation,
even though only single site was measured. If a sub-
strate-selective inhibitor stabilizes the p38-MK2 interac-
tion (or one of many possible forms) it will effectively
sequester and prevent p38 from performing ATF2 phos-
phorylation, regardless of the number of phosphoryla-
tion sites. Consequently, the single phosphorylation site
Figure 11 Dual substrate assay with compounds. Each compound was run in the dual substrate assay: A, SD-0006, B, BIRB 796, C, CMPD1, D,
SD-0006, E, BIRB 796, F CMPD1. Phosphorylation of MK2 by p38 (left panels) was measured at 30 min for either MK2 alone (Δ) or MK2 + ATF2
(□). Phosphorylation of ATF2 by p38 (right panels) was measured at 120 min for either ATF2 alone (▽) or MK2 + ATF2 (□). Data is shown as a
fraction of the maximum value ± standard deviation (n = 2) and IC50 values for each compound/substrate are listed in Table 3.
Table 3 Dual Substrate Assay: Compound IC50 Values
(uM)
Compound phospho-MK2 phospho-ATF2 substrate selectivity
SD-0006 0.20 ± 1.1 0.02 ± 1.1 0.09
BIRB 796 3.6 ± 1.4 0.12 ± 1.1 0.03
CMPD1 41 ± 2.2 27 ± 16 0.66
Virtual Cmpd 0.0019 ± 1.1 0.0006 ± 1.2 0.33
IC50’s are shown ± standard error. Substrate Selectivity = (ATF2 IC50)/(MK2
IC50)
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Page 12 of 17Figure 12 Protein expression levels. A, sample Western blots used for quantitation of total p38a and MK2 protein levels. On these
representative blots, U937 cell lysates from 3 different experiments (lanes [1-4] and [5,6]) are loaded at 5 ug total protein (lanes 1, 3, 5) and 2 ug
total protein (lanes 2, 4, 6), as measured by BCA assay. Recombinant p38-alpha and MK2 standards were loaded using 3-fold dilutions starting
from 1.68 × 10
10 and 1.34 × 10
11 molecules per lanes, respectively. Cell lysates from U937 (n = 11, 13, for p38 and MK2 blots, respectively), Thp-1
(n = 4, 3) and PBMCs (n = 3, 4) were measured. Images were quantified with densitometry and total p38a (open bars) and MK2 (filled bars)
protein expression levels were calculated. Results are shown in B, # of molecules/cell and in C, uM. Data is shown ± standard deviation.
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Page 13 of 17kinetic model was sufficient to describe and predict the
observed behavior of both classical and substrate-selec-
tive model.
To further address the question of how multiple
phosphorylation sites may affect a substrate-selective
inhibitor we constructed a simplified model incorpor-
ating varying numbers of ATF2 and MK2 phosphoryla-
tion sites (Additional File 1 Supplementary Figure S1).
It was found that increasing the number of ATF2
phosphorylation sites resulted in an increased potency
against maximal ATF2 phosphorylation and this was
independent of the number of MK2 phosphorylation
sites. Similarly, increasing MK2 phosphorylation sites
resulted in an increased potency against maximal MK2
phosphorylation (Additional File 2 Supplementary Fig-
ure S2). Importantly, these effects were independent of
compound type. Thus, by having more MK2 phosphor-
ylation sites than ATF2 phosphorylation sites, cells
may naturally achieve substrate-selectivity. It is unclear
what functional role, if any, this plays. Importantly, the
incorporation of multiple phosphorylation sites did not
affect the conclusion that under the condition where
[MK2] > [active p38], a ‘substrate-selective’ inhibitor
will inhibit the phosphorylation of both MK2 and
ATF2.
In three monocytic cell systems we have shown that
total MK2 protein expression does not exceed that of
p38 in resting cells. In a resting cell inactive MK2 is
reported to reside in the nucleus and the active form of
p38 undergoes nuclear import [23]. Thus, when consid-
ering this compartmentalization, the level of MK2 may
even further exceed the level of active p38. Conse-
quently, it is unlikely that substrate selectivity can be
achieved for any nuclear substrates of p38. However,
due to the compartmentalization and the nuclear/cyto-
plasmic shuttling of the active forms, it may be feasible
to obtain substrate-selectivity for cytosolic substrates. In
these cases, however, substrate selectivity is not a gen-
eral property and will vary based on substrate levels and
substrate-dependent kinetic interaction rates.
Our analysis has centered on a simplified model and
experimental system and may differ from in vivo situa-
tions in a number of ways. For example, this work did
not take into account the mechanism by which p38 gets
activated, whether it be via upstream kinases or via
autophosphorylation [24]. It is possible that various inhi-
bitors may bind differently to active and inactive forms
of p38. Further, many p38 compounds have been
observed to inhibit p38 activation as well [25]. Neither
of these phenomena would be expected to affect the
stoichiometric effect by which MK2 levels would soak
up all available active p38 when treated with ‘substrate-
selective’ inhibitors. When one considers that there are
multiple converging pathways on ATF2, MK2 (and
other substrates), as well positive and negative feedback
loops that regulate activity and expression levels of
enzymes and substrates, accurately predicting overall
behavior becomes considerably more complex. Nonethe-
less, our kinetic model provides initial guidance for how
a sub-system of the signaling network may operate and
serves as a building block for adding in additional
complexity.
Conclusions
The analysis presented herein suggests that the sub-
strate-selective mechanism of inhibiting is not an effec-
tive strategy for p38/MK2/ATF2 system in cases where
the concentration of MK2 exceeds the concentration of
p38. This work may point to general properties regard-
ing the substrate-selective inhibitor concept. With
regard to other secondary substrates, beyond ATF2, we
believe they will also be inhibited due to the stoichio-
metric excess of MK2 relative to active p38. Further, we
believe this work contributes to determining biological
conditions that are required for the substrate-selective
inhibitor strategy to be effective. There may be other
kinase-substrate pairs in which the stoichiometry is not
limiting for the substrate-selective mechanism and our
computational model is easily adapted for their evalua-
tion. However, moving closer to the receptor level may
broaden the downstream effects by virtue of being
farther from transcriptional and translational endpoints.
Overall, targeting kinase-substrate complexes may offer
a general approach and new avenue for achieving selec-
tivity for kinases with high structural similarity to other
proteins. The different requirements of targeting the
p38-MK2 complex vs. free p38 may lead us into new
chemical space that could still find alternate avenues to
differentiate from previous p38 inhibitors.
Methods
Biochemical Assay
The ability of active p38 to phosphorylate ATF2, MK2
or both was tested in a biochemical assay. Reagents
were added in the following order: compound, substrate
(s), ATP, p38 for a final reaction volume of 40 ul in low
protein binding 96-well plates (Immulon-1B). Final reac-
tion conditions were 0.5-5 nM p38 (in-house, MKK6-
activated), 50 uM, 100 nM ATF2 (Santa Cruz Biotech-
nology SC-4007) 10 nM MK2 (Upstate 14-349). Reac-
tions were performed in buffer containing 20 mM
HEPES pH 7.5, 10 mM MgCl2, 0.01% BSA, 0.0005%
Tween-20, 2% DMSO and 0.1 mM DTT. Reactions
were quenched with 40 ul of buffer containing 50 mM
HEPES pH 7.5, 30 mM EDTA following different incu-
bation times. Phosphorylated ATF2 and phosphorylated
MK2 were assayed as described below. Compounds
were diluted in DMSO (Sigma).
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Page 14 of 17Phospho-ATF2 Assay
Phospho-ATF2 was measured with the Meso-Scale
Discovery (MSD) platform using an in-house assay.
High-binding MSD plates were spotted with 5 ul of
25 ug/ml rabbit anti-ATF2 (Santa Cruz Biotechnology
SC-187, 25 ug/ml in TBS) andl e f tt od r yo v e r n i g h t .
Plates were blocked with 3% MSD Blocker A in MSD
Tris Wash Buffer for at least 1 hr at RT. 25 ul of sample
was added with 25 ul of antibody cocktail containing
0.2 ug/ml mouse anti-phospho ATF2 (Santa Cruz Bio-
technology SC-8398) and 1 ug/ml goat anti-mouse
sulfo-tag (MSD R32AC-1) diluted in 1% Blocker A in
Tris Wash. Plates were incubated for > 3 hr at RT,
washed 4× with 150 ul MSD Tris Wash Buffer and read
on the Meso-Scale Discovery Sector imager using
2× MSD Read Buffer T.
Phospho-MK2 Assay
Phospho-MK2 was measured with the MSD platform
using an in-house assay. High-binding MSD plates were
spotted with 5 ul of 25 ug/ml goat anti-MK2 (SC-6221,
25 ug/ml in TBS) and left to dry overnight. Plates were
blocked with 3% MSD Blocker A in MSD Tris Wash
Buffer for at least 1 hr at RT. 25 ul of sample was added
with 25 ul of antibody cocktail containing 1 ug/ml
mouse anti-phospho MK3 (Thr 334, in-house antibody)
a n d1u g / m lg o a ta n t i - r a b b i ts u l f o - t a g( M S DR 3 2 A B - 1 )
diluted in 1% Blocker A in Tris Wash Buffer. Plates
were incubated for > 3 hr at RT, washed 4× with 150 ul
MSD Tris Wash Buffer and read on the Meso-Scale Dis-
covery Sector imager using 2× MSD Read Buffer T.
Immunoprecipitation Experiment
Anti-total p38 (A12, Santa Cruz Biotechnology SC-7972)
at 1 ug/ml was bound to Immobilized Protein G (Pierce
20398). 5 nM p38 was incubated with varying amount
of MK2 for 1 hour at RT and then added to p38 anti-
body bound to protein G and incubated o/n at 4°C. The
next day antibody and protein G were washed once with
enzyme buffer, once with IP Buffer (1× TBS, 500 mM
NACl, 20 mM Tris, pH 7.5) and twice more with
enzyme buffer ending in fresh enzyme buffer for the
second kinase reaction with ATF2. After 1 hour stop
buffer was added and assayed for phospho-ATF2 in the
MSD assay.
Cell Culture
U937 and Thp-1 cells were obtained from ATCC and
cultured under the recommended conditions. Prior to
cell plating, cells were differentiated into macrophages
with PMA (Sigma). Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood using Ficoll
gradient centrifugation and maintained in RMPI + 10%
FBS.
Quantitative Western Blotting
U937, Thp-1 cells and PBMCs were counted and lysed.
Following total protein determination via BCA assay
(Pierce), cells/ug was calculated. Cell lysates were run
on SDS-PAGE gels (Invitrogen) at 2 and 5 ug total pro-
tein per well alongside a 5 point standard of recombi-
nant protein (p38-alpha (in-house, full length-GST
tagged), MK2 (in-house, residues 45-400)). Three-fold
dilutions of standards were loaded, starting at 1.68 ×
10
10 and 1.34 × 10
11 molecules per well for p38-alpha
and MK2, respectively. p38-alpha blots were probed
with rabbit anti-p38alpha (Cell Signaling Technology
#9218). MK2 blots were probed with rabbit anti-MK2
(Cell Signaling Technology #3042). Blots were imaged
and bands quantified using densitometry. Protein stan-
dards were used to construct a standard curve, from
which the number of molecules per cell could be calcu-
lated. Numbers were converted into uM, based on
reported cell volumes for the different cell types: 1.09 pl,
0.97 pl and 0.38 pl for U937, Thp-1 and PBMC, respec-
tively [26-28].
Kinetic Model Development
A mass-action kinetic model was built to precisely simu-
late the experimental biochemical reaction conditions.
In the kinetic model, activated p38 reversibly binds ATP
with affinity KD, ATP, independent of further complex
formation. p38 (ATP bound or not) may reversibly com-
plex with either ATF2 or MK2 yielding p38-ATF2, p38:
ATP:ATF2, or p38:MK2, p38:ATP:MK2. Complex for-
mation is characterized by affinities KD, ATF2 and KD,
MK2. p38:ATP:ATF2 and p38:ATP:MK2 undergo a irre-
versible catalysis step yielding phospho-ATF2 and ADP
with rate constant kcat, ATF2 or phospho-MK2 and ADP
with rate constant kcat, MK2.I ti sk n o w nt h a tp 3 8p h o s -
phorylates ATF2 on Thr69 and Thr71 in a two-step dis-
tributive mechanism [19,29] and MK2 on multiple sites
[13], however, for the sake of simplicity we have mod-
eled phosphorylation as a one-step process. Rate con-
stants and literature references are listed in Table 2. All
forward interaction rates are assumed to be diffusion
limited (ATF2 and MK2 forward interaction rate con-
stants with p38 were set to 10
6 M
-1s
-1;A T Pa n dc o m -




-1). Simulations were performed in a 40 ul reac-
tion volume, with 0.5 nM p38, 100 nM ATF2, 10 nM
MK2 and 50 uM ATP.
Additional Kinetic Mechanisms
[1] Substrate Inhibition: phospho-MK2 and phospho-
ATF2 are allowed to re-bind p38 to form phospho-
MK2:p38 and phospho-ATF2:p38. Interactions are
assumed to occur at rates equal to the unphosphory-
lated interactions. [2] phospho-MK2 binds ATF2:
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Page 15 of 17phospho-MK2 is allowed to bind unphosphorylated
ATF2 to form phospho-MK2:ATF2 and thereby block
its interaction with and phosphorylation by p38. It is
assumed that this interaction occurs with the same affi-
nity as the p38-ATF2 interaction [3-5]. After interaction
with MK2, p38 is left in a modified form, p38*. p38*
undergoes the same interactions as before with the
same kinetic constants except for: [3] KD, ATP is lowered
10-fold; [4] KD, ATF2 is lowered 10-fold; and [5] kcat,
ATF2 is lowered 10-fold.
Computations
The kinetic model was coded in Teranode Design Suite
(Teranode Corporation, Seattle, WA). The completed
model was exported in SBML format http://www.sbml.
org. The SBML code was translated into the Jacobian
language (Numerica Technology, Cambridge, MA) using
a translator written in MATLAB (The Mathworks,
Natick, MA) using the SBML toolbox http://sbml.org/
software/sbmltoolbox/. Scripts were written in Jacobian
and MATLAB to generate dose-response curves and fig-
ures. Model files are available in Additional Files 3, 4, 5
and 6. IC50’s were calculated using GraphPad Prism
(GraphPad Software, La Jolla, CA).
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